Educational Symposium
Hyperkalemia: Understanding and Applying Innovative Approaches to the Management of CKD and ESKD
November 05, 2022 | 12:45 PM - 01:45 PM
Location: Regency Ballroom S, Hyatt Regency Orlando
Session Description
Hyperkalemia is defined as a serum potassium concentration greater than 5.0–5.5 mEq/L in adults. In acute or chronic kidney disease, this results from impaired urinary potassium excretion. Hyperkalemia is associated with significant morbidity and mortality in patients with CKD and ESKD. Clinicians typically recommend a multidisciplinary approach that involves modifying the diet; adjusting medication regimens that include RAAS blockers and ACE inhibitors, which can contribute to hyperkalemia; and starting potassium binders.
Understanding hyperkalemia and the latest clinical trial results in patients with CKD and ESKD is vital to improving outcomes. This symposium covers the benefits of pharmacological options for the management of hyperkalemia in CKD and for patients on dialysis.
Support is provided by an educational grant from AstraZeneca Pharmaceuticals.
Learning Objective(s)
- Identify and summarize novel therapies for the treatment of hyperkalemia
- Discuss the relationship between dietary potassium and serum potassium
- Discuss the role of an interdisciplinary team in managing potassium in diet, medications, and behavior to reduce serum potassium
- Describe the challenges of managing hyperkalemia in CKD and ESKD and how it affects patient outcomes
Learning Pathway(s)
- Fluid, Electrolyte, and Acid-Base Disorders
- CKD Non-Dialysis
Moderator
- Kim Zuber, PA, PA-C
Presentations
- Introduction: The Physiology of Hyperkalemia
12:45 PM - 12:55 PM
Kim Zuber, PA, PA-C
- The Impact of Hyperkalemia in the Treatment of CKD
12:55 PM - 01:15 PM
Mitchell H. Rosner, MD, FASN
- Pharmacological and Nonpharmacological Approaches to the Management of Hyperkalemia
01:15 PM - 01:35 PM
Biff F. Palmer, MD, FASN
- Questions and Answers
01:35 PM - 01:45 PM
